Scorpion Therapeutics picks up $162m Series B

Scorpion Therapeutics, Inc., a next-generation precision oncology company, has raised $162 million in Series B financing.

Scorpion Therapeutics, Inc., a next-generation precision oncology company, has raised $162 million in Series B financing. Boxer Capital of Tavistock Group, EcoR1 Capital, LLC, Omega Funds and Vida Ventures led the round.

Source: Press Release